Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: -0.25 (-1.37%)
Spread: 1.00 (5.714%)
Open: 18.25
High: 18.25
Low: 18.00
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Martin Gilbert Joins River & Mercantile

Wed, 06th Jan 2021 14:27

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and not separately reported by Alliance News:

----------

River & Mercantile Group PLC - Hires Martin Gilbert to be deputy chair, starting Wednesday. Gilbert was the co-founder and then chief executive of Aberdeen Asset Management, now Standard Life Aberdeen PLC. He currently is chair of lender Revolut Ltd and senior independent director of miner Glencore PLC. "In the current environment there are market opportunities for RMG, both organic and through acquisitions, that can drive shareholder value," Gilbert says. River & Mercantile had GBP45.4 billion in assets under management as of September 30.

----------

Fulcrum Utility Services Ltd - Sheffield-based multi-utility infrastructure and services provider - Daren Harris steps down as chief executive officer and from board, effective immediately. Chief Operating Officer Terry Dugdale, in post since March 2019, becomes CEO. "The business is well placed with strong market drivers and a robust balance sheet and its strategy is strongly positioned to capitalise on the UK's journey to net zero," Harris says. "Unfortunately, due to personal reasons, I need to step down from the business." He adds: "Since joining the business, Terry has driven our operating efficiency and has made significant progress in preparing the business foundations for the future."

----------

Silence Therapeutics PLC - London-based novel short interfering ribonucleic acid therapeutics developer - Hires Craig Tooman as chief financial officer, effective immediately. Tooman was most recently CFO & COO of Princeton, New Jersey-based Vyome Therapeutic Inc. Silence also says Michael Davidson has joined the Silence board as non-executive director. Davidson currently is CEO of New Amsterdam Pharma BV and a professor of medicine at the Lipid Clinic at the University of Chicago. He founded Omthera Pharmaceuticals in 2008, which was acquired by AstraZeneca PLC in 2013, and was founding CEO of Corvidia Therapeutics, which was acquired by Novo Nordisk AS in 2020.

----------

Personal Group Holdings PLC - Milton Keynes, Buckinghamshire-based provider of employee services - Makes Interim CFO Sarah Mace its permanent CFO, effective immediately. Mace was promoted to the board as interim CFO back in October, having joined Personal Group in 2014.

----------

Kape Technologies PLC - Isle of Man-based digital security and privacy software company - Hires Pierre-Etienne Lallia as non-executive director, effective immediately. Lallia spent 10 years at Nomura International PLC in London, where he was managing director of the Acquisition & Leveraged Finance team. Prior to that, he was with Goldman Sachs International, part of Goldman Sachs Group Inc.

----------

Time Finance PLC - Bath, England-based finance provider to UK small and medium businesses - Non-Executive Chair John Newman and CEO Ian Smith both to retire once successors are found. Says process for replacing the pair is underway. Says Smith's decision follows rebranding of company from 1pm PLC early last month and his previous intention to retire in any event at the end of 2021.

----------

Destiny Pharma PLC - Brighton-based clinical stage biotechnology firm focused on preventing infections - Hires Stephanie Bewick as chief business officer. Bewick was vice president for Business Development at Nasdaq-listed Summit Therapeutics Inc.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Oct 2020 14:42

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

IN BRIEF: Destiny Pharma Set To Complete Study Recruitment By 2020 End

Read more
12 Oct 2020 14:31

Second Covid wave slows patient recruitment for Destiny Pharma

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma updated the market on its 'XF-73' phase 2b clinical study with 101 patients on Monday, out of the target of 125 now recruited.

Read more
17 Sep 2020 19:09

IN BRIEF: Destiny Pharma Notes XF-73 Study Recruitment On Track

IN BRIEF: Destiny Pharma Notes XF-73 Study Recruitment On Track

Read more
17 Sep 2020 15:39

UK EARNINGS SUMMARY: Novacyt Profit Leaps On Covid-19 Test Kit Demand

UK EARNINGS SUMMARY: Novacyt Profit Leaps On Covid-19 Test Kit Demand

Read more
7 Sep 2020 14:34

IN BRIEF: Destiny Pharma To Co-Develop Covid-19 Prevention Product

IN BRIEF: Destiny Pharma To Co-Develop Covid-19 Prevention Product

Read more
7 Sep 2020 08:57

Destiny Pharma enters collaboration deal with SporeGen

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has entered into a collaboration agreement with SporeGen, it announced on Monday, which is a UK biotechnology company working on Bacillus and its applications.

Read more
11 Aug 2020 12:36

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

Read more
27 Jul 2020 21:28

IN BRIEF: Destiny Pharma Amends Component Of XF-73 Phase 2b Trial

IN BRIEF: Destiny Pharma Amends Component Of XF-73 Phase 2b Trial

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
9 Jun 2020 15:51

Destiny Pharma awarded grant for Cardiff research collaboration

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has been jointly awarded a National Biofilms Innovation Centre (NBIC) grant to fund a research collaboration with Cardiff University, it announced on Tuesday.

Read more
9 Jun 2020 13:25

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Read more
3 Jun 2020 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
4 May 2020 12:24

Destiny Pharma's XF-73 Drug Candidate Backed By New Research

Destiny Pharma's XF-73 Drug Candidate Backed By New Research

Read more
3 Mar 2020 16:16

Destiny Pharma Progresses On Patient Recruitment For XF-73 Study

Destiny Pharma Progresses On Patient Recruitment For XF-73 Study

Read more
20 Jan 2020 11:44

Destiny Pharma Completes First Phase Of Collaboration With MedPharm

Destiny Pharma Completes First Phase Of Collaboration With MedPharm

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.